The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 29, 2019
Filed:
Mar. 31, 2016
Applicants:
The Translational Genomics Research Institute, Phoenix, AZ (US);
Washington University, St. Louis, MO (US);
Inventors:
Pamela Pollock, Queensland, AU;
Paul Goodfellow, Columbus, OH (US);
Assignees:
The Translational Genomics Research Institute, Phoenix, AZ (US);
Washington University, St. Louis, MO (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/00 (2006.01); G01N 33/574 (2006.01); G01N 33/68 (2006.01); A61K 31/519 (2006.01); C12N 15/113 (2010.01); C12Q 1/6886 (2018.01);
U.S. Cl.
CPC ...
G01N 33/57442 (2013.01); A61K 31/519 (2013.01); C12N 15/1138 (2013.01); C12Q 1/6886 (2013.01); G01N 33/6893 (2013.01); A61K 35/00 (2013.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01); C12N 2320/30 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01); G01N 2333/71 (2013.01);
Abstract
Diagnostic and therapeutic applications for endometrial cancer are described. The diagnostic and therapeutic applications are based on certain activation mutations in the FGFR2 gene and its expression products. The present invention is directed to nucleotide sequences, amino acid sequences, probes, and primers related to FGFR2 activation mutants and kits comprising these mutants to diagnosis and classify endometrial cancer in a subject.